BriaCell Therapeutics Shares Are Trading Higher After the Company Announced It Dosed the First Patient in Its Phase 1/2 Study of Bria-OTS.

BenzingaNov 21 11:47 ET

Briacell Therapeutics Has Dosed The First Patient In Its Phase 1/2 Study To Evaluate The Safety And Efficacy Of Bria-OTS, Briacell's Personalized Next Generation Immunotherapy

BenzingaNov 21 07:51 ET

BriaCell Showcases Robust Anti-Cancer Activity of Personalized Off-the-Shelf Immunotherapy Pipeline at the 2024 SITC Conference

GlobeNewswireNov 8 07:50 ET

BriaCell Overall Survival Data Selected for Spotlight Poster at 2024 San Antonio Breast Cancer Symposium, December 10 – 13

GlobeNewswireNov 4 07:50 ET

10-K: FY2024 Annual Report

SECOct 29 13:23 ET · Announcements

Express News | Briacell Therapeutics Corp - No Briacell-Imt Related Discontinuations Reported

ReutersOct 22 07:50 ET